Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-02-24 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于修订《公司章程》部分条款的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the revision of certain articles of the company's Articles of Association (公司章程), specifically about changes to the board structure and composition. It mentions the board of directors and the need for shareholder approval at the 2024 annual general meeting. The content focuses on governance structure changes rather than financial results or detailed reports. The document is relatively short (636 characters) and is an announcement of proposed governance changes, not a full governance report or annual report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2025-02-24 Chinese
2024年度独立董事述职报告（张斌）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and shareholder meetings, communication with audit firms, and oversight activities during the year 2024. The content focuses on the independent director's report on their work and responsibilities rather than financial results or audit opinions. It is not an annual report, audit report, or earnings release. It is a specific report by an independent director about their annual duties and observations, which fits the category of Board/Management Information (MANG) as it relates to management and board-level disclosures about governance and director activities. The document length is 3326 characters, which is consistent with a detailed director report rather than a brief announcement or a full financial report. Therefore, the best classification is MANG with high confidence.
2025-02-24 Chinese
天士力2024年度利润分配预案
Notice of Dividend Amount Classification · 100% confidence The document is a profit distribution plan (dividend announcement) for the year 2024 by the company 天士力医药集团股份有限公司. It details the proposed cash dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. It also mentions the need for shareholder approval at the upcoming annual general meeting. The content focuses on dividend amount, payment basis, and related procedural information, which fits the definition of a Notice of Dividend Amount (DIV). The document length is short (1587 characters) and contains specific dividend details rather than just an announcement of a report or a regulatory filing. Therefore, the correct classification is Notice of Dividend Amount (DIV).
2025-02-24 Chinese
天士力关于2025年度使用闲置资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding the use of idle funds for entrusted financial management in 2024. It details the investment purpose, amount, risk analysis, and risk control measures. The document is a formal announcement about a financing activity involving the company's own funds and investment products, but it does not contain financial statements or detailed financial results. It is not a report like an annual or interim report, nor is it a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management through entrusted financial products.
2025-02-24 Chinese
天士力2024年年度报告
Annual Report Classification · 100% confidence The document is titled "天士力医药集团股份有限公司 2024 年年度报告" which translates to "TASLY Pharmaceutical Group Co., Ltd. 2024 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, governance, environmental and social responsibility, and audited financial statements. The document includes signatures from the board and auditors, audit opinions, and comprehensive financial and operational information for the fiscal year ending December 31, 2024. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. These characteristics align with the definition of an Annual Report (10-K). FY 2024
2025-02-24 Chinese
天士力关于购买及出售土地使用权及地上建筑物资产暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the purchase and sale of land use rights and buildings between the company and its controlling shareholder, which constitutes a related party transaction. It details the transaction terms, asset evaluations, board approvals, and independent director opinions. The document is a formal public announcement of a related party transaction, not a full financial report or audit. It does not contain comprehensive financial statements or quarterly/yearly results. It is not a report publication announcement since it contains substantive transaction details and evaluations. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2025-02-24 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.